Ranjana H Advani

List of Publications by Year
in descending order

221 papers	23,712 citations	18465 62 h-index	7944 149 g-index
224 all docs	224 docs citations	224 times ranked	20146 citing authors

#	Article	IF	Citations
1	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood, 2022, 139, 413-423.	0.6	50
2	Venetoclax in Previously Treated WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2022, 40, 63-71.	0.8	53
3	Anti-CD79B Antibodyâ€“Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study. Clinical Cancer Research, 2022, 28, 1294-1301.	3.2	12
4	Current Frontline Treatment of Diffuse Large B-Cell Lymphoma. Oncology, 2022, 36, 51-58.	0.4	5
5	CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity. Blood Cancer Discovery, 2022, 3, 95-102.	2.6	36
6	First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1.. Journal of Clinical Oncology, 2022, 40, 7503-7503.	0.8	9
7	Partial response or better at sixÂmonths is prognostic of superior progressionâ€free survival in WaldenstrÃ¶m macroglobulinaemia patients treated with ibrutinib. British Journal of Haematology, 2021, 192, 542-550.	1.2	8
8	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2021, 39, 565-575.	0.8	98
9	Correlation of 18-fluorodeoxyglucose PET/computed tomography parameters and clinical features to predict outcome for diffuse large B-cell lymphoma. Nuclear Medicine Communications, 2021, 42, 792-799.	0.5	2
10	Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project. Blood, 2021, 138, 213-220.	0.6	53
11	Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Advances, 2021, 5, 1648-1659.	2.5	28
12	Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood, 2021, 138, 427-438.	0.6	109
13	18F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2883-2893.	3.3	8
14	First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers.. Journal of Clinical Oncology, 2021, 39, 3006-3006.	0.8	5
15	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematology,the, 2021, 8, e410-e421.	2.2	83
16	Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. Journal of Clinical Oncology, 2021, 39, 2257-2265.	0.8	32
17	Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. Blood Advances, 2021, 5, 3623-3632.	2.5	11
18	The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell, 2021, 39, 1422-1437.e10.	7.7	102

#	Article	IF	Citations
19	Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant. Blood, 2021, 138, 878-878.	0.6	3
20	Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. Acta Haematologica, 2020, 143, 40-50.	0.7	27
21	Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. American Journal of Hematology, 2020, 95, 151-155.	2.0	43
22	Consensus Statement on the Management of WaldenstrÃ¶m Macroglobulinemia Patients During the COVIDâ€19ÂPandemic. HemaSphere, 2020, 4, e433.	1.2	11
23	Consensus treatment recommendations from the tenth International Workshop for WaldenstrÃ¶m Macroglobulinaemia. Lancet Haematology,the, 2020, 7, e827-e837.	2.2	96
24	Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. Oncologist, 2020, 25, 878-885.	1.9	28
25	Utility of Routine Surveillance Laboratory Testing in Detecting Relapse in Patients With Classic Hodgkin Lymphoma in First Remission: Results From a Large Single-Institution Study. JCO Oncology Practice, 2020, 16, e902-e911.	1.4	1
26	Checkpoint blockade treatment sensitises relapsed/refractory nonâ€Hodgkin lymphoma to subsequent therapy. British Journal of Haematology, 2020, 191, 44-51.	1.2	19
27	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood, 2020, 135, 735-742.	0.6	86
28	Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. Blood Advances, 2020, 4, 253-262.	2.5	29
29	Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. Oncologist, 2020, 25, e993-e997.	1.9	7
30	Threeâ€year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. British Journal of Haematology, 2020, 189, e86-e90.	1.2	25
31	PD-L1 Pathway Markers and Chromosome 9p24.1 Alterations in Patients with Classic Hodgkin Lymphoma Treated with Frontline Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy. Blood, 2020, 136, 17-18.	0.6	0
32	Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study. Blood, 2020, 136, 45-46.	0.6	0
33	Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. Journal of Clinical Oncology, 2019, 37, 3359-3368.	0.8	161
34	The role of autologous stem cell transplantation in patients with nodal peripheral Tâ€cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer, 2019, 125, 1507-1517.	2.0	106
35	Reply to J. Wang et al. Journal of Clinical Oncology, 2019, 37, 755-757.	0.8	2
36	Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematology,the, 2019, 6, e254-e265.	2.2	184

#	Article	IF	Citations
37	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Clinical Cancer Research, 2019, 25, 1718-1726.	3.2	26
38	Modern principles in the management of nodular lymphocyteâ€predominant Hodgkin lymphoma. British Journal of Haematology, 2019, 184, 17-29.	1.2	19
39	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet, The, 2019, 393, 229-240.	6.3	517
40	Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study. Blood, 2019, 134, 238-238.	0.6	18
41	A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma. Blood, 2019, 134, 2834-2834.	0.6	1
42	Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study. Blood, 2019, 134, 468-468.	0.6	8
43	An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma. Blood, 2019, 134, 655-655.	0.6	4
44	Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents. Blood, 2019, 134, 2022-2022.	0.6	4
45	Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis. Blood, 2019, 134, 4027-4027.	0.6	0
46	Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma. Blood, 2019, 134, 4571-4571.	0.6	1
47	North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma. Blood, 2019, 134, 1553-1553.	0.6	0
48	Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study. Blood, 2019, 134, 4026-4026.	0.6	0
49	Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. Blood, 2018, 131, 2120-2124.	0.6	56
50	The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1100-1118.	0.4	46
51	Peripheral T cell lymphoma, not otherwise specified (PTCLâ€NOS). A new prognostic model developed by the International T cell Project Network. British Journal of Haematology, 2018, 181, 760-769.	1.2	49
52	Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood, 2018, 132, 40-48.	0.6	199
53	Ibrutinibâ€associated rash: a singleâ€centre experience of clinicopathological features and management. British Journal of Haematology, 2018, 180, 164-166.	1.2	45
54	How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1Âh: the Stanford Approach. Molecular Imaging and Biology, 2018, 20, 324-335.	1.3	29

#	Article	IF	Citations
55	Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. Cancer, 2018, 124, 136-144.	2.0	47
56	Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood, 2018, 131, 1183-1194.	0.6	276
57	New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 626-636.	1.8	7
58	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2018, 36, 2845-2853.	0.8	313
59	Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. Journal of Clinical Oncology, 2018, 36, 3015-3022.	0.8	102
60	Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05). Oncotarget, 2018, 9, 766-773.	0.8	8
61	CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkinâ€™s Lymphoma. New England Journal of Medicine, 2018, 379, 1711-1721.	13.9	796
62	Risk-adapted therapy for advanced-stage Hodgkin lymphoma. Hematology American Society of Hematology Education Program, 2018, 2018, 200-206.	0.9	14
63	Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation. Clinical Cancer Research, 2018, 24, 4110-4118.	3.2	77
64	Impact of ibrutinib dose intensity on patient outcomes in previously treated WaldenstrÃ¶m macroglobulinemia. Haematologica, 2018, 103, e466-e468.	1.7	18
65	Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy. Radiotherapy and Oncology, 2018, 129, 507-512.	0.3	1
66	Novel Approaches in WaldenstrÃ¶m Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 875-890.	0.9	4
67	First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget, 2018, 9, 13023-13035.	0.8	70
68	Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing). Blood, 2018, 132, 1635-1635.	0.6	9
69	Phase I/II Study of CHOEP Plus Lenalidomide As Initial Therapy for Patients with Stage II-IV Peripheral T-Cell Lymphoma: Phase II Results. Blood, 2018, 132, 2899-2899.	0.6	10
70	A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I). Blood, 2018, 132, 679-679.	0.6	13
71	Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study. Blood, 2018, 132, 2937-2937.	0.6	2
72	Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy. Blood, 2018, 132, 1626-1626.	0.6	7

#	Article	IF	Citations
73	Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F). Blood, 2018, 132, 623-623.	0.6	1
74	Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy. Blood, 2018, 132, 93-93.	0.6	0
75	Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing. Blood, 2018, 132, 2861-2861.	0.6	0
76	A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408. Blood, 2018, 132, 4157-4157.	0.6	0
77	Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma. Blood, 2018, 132, 2838-2838.	0.6	1
78	Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 193-200.	0.2	27
79	Acquired mutations associated with ibrutinib resistance in WaldenstrÃ¶m macroglobulinemia. Blood, 2017, 129, 2519-2525.	0.6	115
80	A prospective cohort study of patients with peripheral Tâ€cell lymphoma in the United States. Cancer, 2017, 123, 1174-1183.	2.0	51
81	Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood, 2017, 130, 2709-2717.	0.6	176
82	Phase I Study of the Anti-CD22 Antibodyâ€“Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Cancer Research, 2017, 23, 1167-1176.	3.2	77
83	Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Leukemia and Lymphoma, 2017, 58, 1607-1616.	0.6	46
84	Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center. Journal of Oncology Practice, 2017, 13, e673-e682.	2.5	3
85	Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma. Blood, 2017, 130, 826-826.	0.6	4
86	Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood, 2017, 130, 649-649.	0.6	7
87	Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e376-e385.	1.8	3
88	A phase <scp>II</scp> study of cyclophosphamide, etoposide, vincristine and prednisone (<scp>CEOP</scp>) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral Tâ€cell lymphoma (<scp>PTCL</scp>): final results from the Tâ€•cell consortium trial. British Journal of Haematology, 2016, 172, 535-544.	1.2	71
89	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. Archives of Pathology and Laboratory Medicine, 2016, 140, 1225-1227.	1.2	6
90	NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1067-1079.	2.3	107

#	Article	IF	Citations
91	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. Journal of Clinical Oncology, 2016, 34, 2690-2697.	0.8	634
92	The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 2016, 127, 2375-2390.	0.6	5,965
93	Treatment recommendations from the Eighth International Workshop on WaldenstrÃ¶mâ€™s Macroglobulinemia. Blood, 2016, 128, 1321-1328.	0.6	161
94	Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood, 2016, 128, 2489-2496.	0.6	370
95	Ibrutinib in WaldenstrÃ¶m macroglobulinemia: latest evidence and clinical experience. Therapeutic Advances in Hematology, 2016, 7, 179-186.	1.1	28
96	Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Science Translational Medicine, 2016, 8, 364ra155.	5.8	348
97	Classical Hodgkin Lymphoma with Reduced Î²2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Cancer Immunology Research, 2016, 4, 910-916.	1.6	146
98	Speeding up PET/MR for cancer staging of children and young adults. European Radiology, 2016, 26, 4239-4248.	2.3	20
99	Clonal architecture of <scp>CXCR</scp>4 <scp>WHIM</scp>â€like mutations in WaldenstrÃ¶m Macroglobulinaemia. British Journal of Haematology, 2016, 172, 735-744.	1.2	122
100	Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring. Radiology, 2016, 280, 220-229.	3.6	39
101	A single-institution retrospective analysis of outcomes for stage Iâ€“II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. Leukemia and Lymphoma, 2016, 57, 604-608.	0.6	12
102	Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL). Blood, 2016, 128, 104-104.	0.6	14
103	Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood, 2016, 128, 1105-1105.	0.6	17
104	Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K-Î´,Î³ Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab. Blood, 2016, 128, 2979-2979.	0.6	12
105	Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia. Blood, 2016, 128, 2984-2984.	0.6	8
106	Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial. Blood, 2016, 128, 2992-2992.	0.6	5
107	Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas. Blood, 2016, 128, 2993-2993.	0.6	5
108	Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Blood, 2016, 128, 4144-4144.	0.6	9

#	Article	IF	Citations
109	Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy. Blood, 2016, 128, 621-621.	0.6	16
110	Molecular Basis of Ibrutinib Resistance in Waldenstrom's Macroglobulinemia. Blood, 2016, 128, 756-756.	0.6	1
111	The Outcome of Patients with Primary Refractory or Relapsed Peripheral T-Cell Lymphoma: Analysis of 1020 Cases Registered in the Prospective T-Cell Project. Blood, 2016, 128, 921-921.	0.6	1
112	Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 2930-2930.	0.6	8
113	Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma. Clinical Advances in Hematology and Oncology, 2016, 14, 543-54.	0.3	10
114	XVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma. Hematological Oncology, 2015, 33, 90-95.	0.8	7
115	Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood, 2015, 125, 1394-1402.	0.6	242
116	Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood, 2015, 126, 739-745.	0.6	349
117	Gray zone lymphoma with features intermediate between classical <scp>H</scp>odgkin lymphoma and diffuse large <scp>B</scp>â€cell lymphoma: <scp>C</scp>haracteristics, outcomes, and prognostication among a large multicenter cohort. American Journal of Hematology, 2015, 90, 778-783.	2.0	71
118	Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leukemia and Lymphoma, 2015, 56, 2569-2578.	0.6	36
119	A Phase <scp>II</scp> trial of Belinostat (<scp>PXD</scp>101) in patients with relapsed or refractory peripheral or cutaneous Tâ€cell lymphoma. British Journal of Haematology, 2015, 168, 811-819.	1.2	172
120	Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Cancer Chemotherapy and Pharmacology, 2015, 75, 111-121.	1.1	58
121	Anxiety and Health-Related Quality of Life Among Patients With Lowâ€“Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT). Journal of Clinical Oncology, 2015, 33, 740-748.	0.8	36
122	Value of Surveillance Studies for Patients With Stage I to II Diffuse Large B-Cell Lymphoma in the Rituximab Era. International Journal of Radiation Oncology Biology Physics, 2015, 92, 99-106.	0.4	13
123	Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nature Medicine, 2015, 21, 922-926.	15.2	927
124	Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and SÃ©zary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of Clinical Oncology, 2015, 33, 3750-3758.	0.8	235
125	Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma in the Modern Era. International Journal of Radiation Oncology Biology Physics, 2015, 92, 67-75.	0.4	9
126	Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. Journal of Clinical Oncology, 2015, 33, 1936-1942.	0.8	33

#	Article	IF	Citations
127	Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the <scp>BCL</scp>2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory <scp>CD</scp>20⁺ lymphoid malignancies. British Journal of Haematology, 2015, 170, 669-678.	1.2	80
128	Responseâ€adapted therapy for aggressive nonâ€Hodgkin's lymphomas based on early [18F] FDGâ€PET scanning: ECOGâ€ACRIN Cancer Research Group study (E3404). British Journal of Haematology, 2015, 170, 56-65.	1.2	50
129	Ibrutinib in Previously Treated WaldenstrÃ¶mâ€™s Macroglobulinemia. New England Journal of Medicine, 2015, 372, 1430-1440.	13.9	810
130	Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leukemia and Lymphoma, 2015, 56, 703-710.	0.6	29
131	The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability. Blood, 2015, 126, 1486-1486.	0.6	1
132	Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis. Blood, 2015, 126, 1536-1536.	0.6	3
133	Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia. Blood, 2015, 126, 1540-1540.	0.6	8
134	A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refactory B-Lineage Non-Hodgkin Lymphoma. Blood, 2015, 126, 182-182.	0.6	35
135	Long-Term Follow-up and Analysis of Dose Groups with Ibrutinib in Relapsed Follicular Lymphoma. Blood, 2015, 126, 2706-2706.	0.6	8
136	Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study. Blood, 2015, 126, 470-470.	0.6	31
137	Ibrutinib-Associated Rash: Single-Center Experience of Clinicopathologic Features and Management. Blood, 2015, 126, 4860-4860.	0.6	4
138	Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412). Blood, 2015, 126, 585-585.	0.6	25
139	Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2015, 33, 8506-8506.	0.8	5
140	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. Blood, 2015, 126, 176-176.	0.6	4
141	Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y90-Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499. Blood, 2015, 126, 2702-2702.	0.6	0
142	A multicentre study of primary breast diffuse large <scp>B</scp>â€cell lymphoma in the rituximab era. British Journal of Haematology, 2014, 165, 358-363.	1.2	91
143	Brutonâ€™s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Therapeutic Advances in Hematology, 2014, 5, 121-133.	1.1	57
144	A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. Journal of Hematology and Oncology, 2014, 7, 44.	6.9	76

#	Article	IF	Citations
145	Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30⁺ Peripheral T-Cell Lymphomas: Results of a Phase I Study. Journal of Clinical Oncology, 2014, 32, 3137-3143.	0.8	153
146	Customized Targeted Therapy in Hodgkin Lymphoma. Hematology/Oncology Clinics of North America, 2014, 28, 105-122.	0.9	6
147	ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma. Journal of the American College of Radiology, 2014, 11, 1026-1033.e3.	0.9	16
148	Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyteâ€“Predominant Hodgkin Lymphoma. Journal of Clinical Oncology, 2014, 32, 912-918.	0.8	96
149	Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. Journal of Hematology and Oncology, 2014, 7, 24.	6.9	144
150	Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood, 2014, 123, 3095-3100.	0.6	280
151	Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma. Blood, 2014, 124, 1741-1741.	0.6	14
152	Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study. Blood, 2014, 124, 1745-1745.	0.6	4
153	Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma. Blood, 2014, 124, 3092-3092.	0.6	13
154	Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Blood, 2014, 124, 3095-3095.	0.6	14
155	Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study. Blood, 2014, 124, 4453-4453.	0.6	13
156	Brentuximab Vedotin Monotherapy in DLBCL Patients with Undetectable CD30: Preliminary Results from a Phase 2 Study. Blood, 2014, 124, 629-629.	0.6	5
157	Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology, 2014, 32, 8505-8505.	0.8	8
158	Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology, 2014, 32, 8519-8519.	0.8	16
159	Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL.. Journal of Clinical Oncology, 2014, 32, 8504-8504.	0.8	0
160	Value of surveillance studies for patients (pts) with stage I-II diffuse large B-cell lymphoma (DLBCL) in the rituximab (R) era.. Journal of Clinical Oncology, 2014, 32, 8544-8544.	0.8	0
161	Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome. Blood, 2014, 124, 1703-1703.	0.6	0
162	Bulky mediastinal classical Hodgkin lymphoma in young women. Oncology, 2014, 28, 253-6, 258-60, C3.	0.4	2

#	Article	IF	Citations
163	Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. New England Journal of Medicine, 2013, 369, 507-516.	13.9	1,449
164	A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leukemia and Lymphoma, 2013, 54, 1373-1379.	0.6	65
165	Gene Expressionâ€"Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma. Journal of Clinical Oncology, 2013, 31, 692-700.	0.8	176
166	Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). Journal of Clinical Oncology, 2013, 31, 684-691.	0.8	256
167	Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma. New England Journal of Medicine, 2013, 368, 1408-1416.	13.9	485
168	The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and <scp>S</scp>tanford <scp>V</scp> in older <scp>H</scp>odgkin lymphoma patients: a comprehensive analysis from the <scp>N</scp>orth <scp>A</scp>merican intergroup trial <scp>E</scp>2496. British Journal of Haematology, 2013, 161, 76-86.	1.2	111
169	Cancer Vaccines and T Cell Therapy. Biology of Blood and Marrow Transplantation, 2013, 19, S97-S101.	2.0	9
170	How I treat nodular lymphocyte predominant Hodgkin lymphoma. Blood, 2013, 122, 4182-4188.	0.6	45
171	Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies. Journal of Clinical Oncology, 2013, 31, 88-94.	0.8	991
172	Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood, 2013, 121, 745-751.	0.6	105
173	Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood, 2013, 121, 3547-3553.	0.6	117
174	A Prospective Multicenter Study Of The Brutonâ€™s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstromâ€™s Macroglobulinemia. Blood, 2013, 122, 251-251.	0.6	34
175	A Phase II Study Of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Peripheral T-Cell Lymphoma (PTCL): Preliminary Results From The T- Cell Consortium Trial. Blood, 2013, 122, 3044-3044.	0.6	2
176	Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. Blood, 2013, 122, 4277-4277.	0.6	3
177	Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas. Blood, 2013, 122, 4386-4386.	0.6	6
178	A Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results In Patients With DLBCL and Other B-Cell Lymphomas. Blood, 2013, 122, 848-848.	0.6	33
179	Improved Risk Stratification With Addition Of Male Sex (S) To The Elderly International Prognostic Index (S-EIPI) For DLBCL Patients > 60 Years Treated With R-CHOP: An International Collaboration Of The US Intergroup, German High-Grade Non-Hodgkin Lymphoma Study Group and Groupe dâ€™Etude De Lymphome dâ€™Adultes. Blood, 2013, 122, 3045-3045.	0.6	2
180	Germinal Center Kinase Regulates The Proliferation and Survival Of Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 643-643.	0.6	0

#	Article	IF	Citations
181	Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90â€“Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. Journal of Clinical Oncology, 2012, 30, 3119-3126.	0.8	86
182	Brentuximab Vedotin in Transplant-NaÃ¯ve Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies. Oncologist, 2012, 17, 1073-1080.	1.9	42
183	Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood, 2012, 120, 560-568.	0.6	157
184	Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. Leukemia and Lymphoma, 2012, 53, 718-720.	0.6	26
185	Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood, 2012, 120, 3280-3287.	0.6	188
186	Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. Journal of Clinical Oncology, 2012, 30, 2190-2196.	0.8	890
187	A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. Clinical Cancer Research, 2012, 18, 248-255.	3.2	204
188	Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity. Blood, 2012, 120, 1618-1618.	0.6	2
189	Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.. Blood, 2012, 120, 2745-2745.	0.6	6
190	A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results.. Blood, 2012, 120, 2746-2746.	0.6	9
191	Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas. Blood, 2012, 120, 60-60.	0.6	32
192	Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression. Blood, 2012, 120, 797-797.	0.6	15
193	Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience.. Journal of Clinical Oncology, 2012, 30, 8060-8060.	0.8	0
194	Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study.. Journal of Clinical Oncology, 2012, 30, 8070-8070.	0.8	2
195	Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years. Blood, 2012, 120, 4779-4779.	0.6	0
196	Stage I-IIA Non-Bulky Hodgkin's Lymphoma. Is Further Distinction Based on Prognostic Factors Useful? The Stanford Experience. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1374-1379.	0.4	11
197	MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP. Clinical Cancer Research, 2011, 17, 4125-4135.	3.2	126
198	Optimal Therapy of Advanced Hodgkin Lymphoma. Hematology American Society of Hematology Education Program, 2011, 2011, 310-316.	0.9	21

#	Article	IF	Citations
199	Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496. Blood, 2011, 118, 1603-1603.	0.6	3
200	Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas. Blood, 2011, 118, 3091-3091.	0.6	6
201	A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia,. Blood, 2011, 118, 3701-3701.	0.6	13
202	Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL),. Blood, 2011, 118, 3711-3711.	0.6	8
203	The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial. Blood, 2011, 118, 442-442.	0.6	14
204	Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update. Blood, 2011, 118, 443-443.	0.6	11
205	Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis. Blood, 2011, 118, 94-94.	0.6	4
206	Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results. Blood, 2011, 118, 3068-3068.	0.6	0
207	Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules. Clinical Cancer Research, 2010, 16, 2167-2175.	3.2	42
208	Risk stratification in extranodal natural killer/T-cell lymphoma. Expert Review of Anticancer Therapy, 2010, 10, 1395-1405.	1.1	7
209	Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Blood, 2010, 116, 961-961.	0.6	13
210	Outcome of Patients with Advanced Hodgkin Lymphoma Who Are Either Refractory to or Relapsed After Primary Therapy with the Stanford V Regimen. Blood, 2010, 116, 4828-4828.	0.6	0
211	Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2009, 27, 4371-4377.	0.8	175
212	Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine. Leukemia and Lymphoma, 2007, 48, 521-525.	0.6	73
213	Results of a Prospective Phase II Trial of Limited and Extended Rituximab Treatment in Nodular Lymphocyte Predominant Hodgkinâ€™s Disease (NLPHD).. Blood, 2007, 110, 644-644.	0.6	17
214	Management of Advanced Stage Hodgkin Lymphoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2006, 4, 241-247.	2.3	11
215	SGN-40 (Anti-huCD40 mAb) Monotherapy Induces Durable Objective Responses in Patients with Relapsed Aggressive Non-Hodgkinâ€™s Lymphoma: Evidence of Antitumor Activity from a Phase I Study.. Blood, 2006, 108, 695-695.	0.6	19
216	Assessment of Favorable (F) Versus Unfavorable (U) Early Stage Hodgkinâ€™s Disease (HD); the Stanford V + Radiotherapy (RT) Experience.. Blood, 2005, 106, 1932-1932.	0.6	17

#	Article	IF	Citations
217	Phase II Study of Bortezomib in Waldenstromâ€™s Macroglobulinemia: Results of WMCTG Trial 03-248.. Blood, 2005, 106, 490-490.	0.6	8
218	Motexafin Gadolinium (MGd) Has Clinical Activity in Relapsed/Refractory Low Grade Lymphomas (LG) and Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).. Blood, 2005, 106, 4758-4758.	0.6	1
219	Stage I and II Follicular Non-Hodgkinâ€™s Lymphoma: Long-Term Follow-Up of No Initial Therapy. Journal of Clinical Oncology, 2004, 22, 1454-1459.	0.8	211
220	A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C ?, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer, 2004, 100, 321-326.	2.0	65
221	Efficacy and Late Effects of Stanford V Chemotherapy and Radiotherapy in Untreated Hodgkinâ€™s Disease: Mature Data in Early and Advanced Stage Patients.. Blood, 2004, 104, 308-308.	0.6	22